Skip to content

Relationship between local control rate and overall survival rate in stereotactic body radiotherapy for early-stage lung cancer: systematic review

Relationship between local control rate and overall survival rate in stereotactic body radiotherapy for early-stage lung cancer: systematic review - Relationship between local control rate and overall survival rate in stereotactic body radiotherapy for early-stage lung cancer: systematic review

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000046913
Enrollment
Unknown
Registered
2022-04-01
Start date
2022-04-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Interventions

None listed

Sponsors

Ofuna Chuo Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients with NSCLC staged as T1-2N0 treated with SBRT are aimed for the study. We will include studies in which dose prescription methods and local control rate were described. Articles with at least 25 cases and a median follow-up duration of at least 12 months was included.Articles were published as full reports. Non-English reports will be excluded.The reports are permitted for centrally located tumors, or T3 or T4 tumors consisted of less than 30% of the entire study population.

Exclusion criteria

Exclusion criteria: Articles including metastasis or articles which overall survival and local control rates are not determined on a one-to-one basis will be excluded. Studies involving patients with metastatic lung tumors, postoperative recurrence or lymph node metastases, or studies restricted to elderly patients are excluded. The reports were excluded if patients are recruited for a certain property of the tumor or patients characteristics such as pathology, ground-glass opacity, operability, or interstitial pneumonia. Data that only reported outcomes for specific patient groups (e.g., operable vs. inoperable) or tumor groups (e.g., histologically proven vs. unproven) and for which no overall outcome was given are excluded. Studies including particle therapy and concurrent chemotherapy are excluded. Concurrent chemotherapy is not permitted.

Design outcomes

Primary

MeasureTime frame
Meta-regression analysis to investigate correlation coefficient between local control and overall survival

Secondary

MeasureTime frame
Meta-regression analysis to investigate correlation coefficient between local control and outcomes including cancer-specific survival, distant metastases-free survival, and disease-free survival

Countries

Japan

Contacts

Public ContactNaoko Naoko

Ofuna Chuo Hospital Radiation Oncology Center

naokosanuki@icloud.com0467452111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026